|
Collaborations (Details) (USD $) In Millions, unless otherwise specified
|
1 Months Ended |
3 Months Ended |
12 Months Ended |
1 Months Ended |
6 Months Ended |
1 Months Ended |
12 Months Ended |
3 Months Ended |
1 Months Ended |
10 Months Ended |
|
Dec. 31, 2013
|
Dec. 31, 2014
|
Sep. 30, 2014
|
Jun. 30, 2014
|
Mar. 31, 2014
|
Dec. 31, 2013
|
Sep. 30, 2013
|
Jun. 30, 2013
|
Mar. 31, 2013
|
Dec. 31, 2014
|
Dec. 31, 2013
|
Dec. 31, 2012
|
Aug. 31, 2012
|
Oct. 31, 2013
|
Nov. 30, 2011
|
Jun. 30, 2011
|
Dec. 31, 2009
|
Dec. 31, 2011
|
Mar. 31, 2011
|
Dec. 31, 2012
|
Jun. 30, 2001
|
Oct. 31, 2011
|
| Collaboration and other revenue |
|
|
|
|
|
|
|
|
|
$ 788.4us-gaap_OtherSalesRevenueNet |
$ 707.5us-gaap_OtherSalesRevenueNet |
$ 633.0us-gaap_OtherSalesRevenueNet |
|
|
|
|
|
|
|
|
|
|
| Total Revenue |
|
5,121.3us-gaap_Revenues |
4,875.6us-gaap_Revenues |
4,935.6us-gaap_Revenues |
4,683.1us-gaap_Revenues |
5,808.8us-gaap_Revenues |
5,772.6us-gaap_Revenues |
5,929.7us-gaap_Revenues |
5,602.0us-gaap_Revenues |
19,615.6us-gaap_Revenues |
23,113.1us-gaap_Revenues |
22,603.4us-gaap_Revenues |
|
|
|
|
|
|
|
|
|
|
| Other Nonoperating Income (Expense) |
|
|
|
|
|
|
|
|
|
368.3us-gaap_OtherNonoperatingIncomeExpense |
63.9us-gaap_OtherNonoperatingIncomeExpense |
(41.0)us-gaap_OtherNonoperatingIncomeExpense |
|
|
|
|
|
|
|
|
|
|
| Research and Development Expense |
|
|
|
|
|
|
|
|
|
4,733.6us-gaap_ResearchAndDevelopmentExpense |
5,531.3us-gaap_ResearchAndDevelopmentExpense |
5,278.1us-gaap_ResearchAndDevelopmentExpense |
|
|
|
|
|
|
|
|
|
|
| Proceeds from prepayment of revenue-sharing obligation |
|
|
|
|
|
|
|
|
|
0us-gaap_ProceedsFromSaleOfIntangibleAssets |
0us-gaap_ProceedsFromSaleOfIntangibleAssets |
1,212.1us-gaap_ProceedsFromSaleOfIntangibleAssets |
|
|
|
|
|
|
|
|
|
|
| Other-net, (income) expense |
|
137.2us-gaap_NonoperatingIncomeExpense |
93.5us-gaap_NonoperatingIncomeExpense |
53.8us-gaap_NonoperatingIncomeExpense |
56.0us-gaap_NonoperatingIncomeExpense |
9.1us-gaap_NonoperatingIncomeExpense |
(31.3)us-gaap_NonoperatingIncomeExpense |
11.9us-gaap_NonoperatingIncomeExpense |
529.2us-gaap_NonoperatingIncomeExpense |
340.5us-gaap_NonoperatingIncomeExpense |
518.9us-gaap_NonoperatingIncomeExpense |
674.0us-gaap_NonoperatingIncomeExpense |
|
|
|
|
|
|
|
|
|
|
| Marketing, selling, and administrative |
|
|
|
|
|
|
|
|
|
6,620.8us-gaap_SellingGeneralAndAdministrativeExpense |
7,125.6us-gaap_SellingGeneralAndAdministrativeExpense |
7,513.5us-gaap_SellingGeneralAndAdministrativeExpense |
|
|
|
|
|
|
|
|
|
|
| Acquired in-process research and development |
57.1lly_AcquiredInProcessResearchAndDevelopment |
105.2lly_AcquiredInProcessResearchAndDevelopment |
95.0lly_AcquiredInProcessResearchAndDevelopment |
0lly_AcquiredInProcessResearchAndDevelopment |
0lly_AcquiredInProcessResearchAndDevelopment |
57.1lly_AcquiredInProcessResearchAndDevelopment |
0lly_AcquiredInProcessResearchAndDevelopment |
0lly_AcquiredInProcessResearchAndDevelopment |
0lly_AcquiredInProcessResearchAndDevelopment |
200.2lly_AcquiredInProcessResearchAndDevelopment |
57.1lly_AcquiredInProcessResearchAndDevelopment |
0lly_AcquiredInProcessResearchAndDevelopment |
|
|
|
|
|
|
|
|
|
|
| Amortization of Intangible Assets |
|
|
|
|
|
|
|
|
|
535.9us-gaap_AmortizationOfIntangibleAssets |
555.0us-gaap_AmortizationOfIntangibleAssets |
563.0us-gaap_AmortizationOfIntangibleAssets |
|
|
|
|
|
|
|
|
|
|
| Erbitux [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sales Revenue, Goods, Net |
|
|
|
|
|
|
|
|
|
46.1us-gaap_SalesRevenueGoodsNet / us-gaap_ProductOrServiceAxis = lly_ErbituxMember |
58.5us-gaap_SalesRevenueGoodsNet / us-gaap_ProductOrServiceAxis = lly_ErbituxMember |
76.4us-gaap_SalesRevenueGoodsNet / us-gaap_ProductOrServiceAxis = lly_ErbituxMember |
|
|
|
|
|
|
|
|
|
|
| Collaboration and other revenue |
|
|
|
|
|
|
|
|
|
327.2us-gaap_OtherSalesRevenueNet / us-gaap_ProductOrServiceAxis = lly_ErbituxMember |
315.2us-gaap_OtherSalesRevenueNet / us-gaap_ProductOrServiceAxis = lly_ErbituxMember |
320.6us-gaap_OtherSalesRevenueNet / us-gaap_ProductOrServiceAxis = lly_ErbituxMember |
|
|
|
|
|
|
|
|
|
|
| Total Revenue |
|
|
|
|
|
|
|
|
|
373.3us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_ErbituxMember |
373.7us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_ErbituxMember |
397.0us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_ErbituxMember |
|
|
|
|
|
|
|
|
|
|
| Effient [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sales Revenue, Goods, Net |
|
|
|
|
|
|
|
|
|
522.2us-gaap_SalesRevenueGoodsNet / us-gaap_ProductOrServiceAxis = lly_EffientMember |
508.7us-gaap_SalesRevenueGoodsNet / us-gaap_ProductOrServiceAxis = lly_EffientMember |
457.2us-gaap_SalesRevenueGoodsNet / us-gaap_ProductOrServiceAxis = lly_EffientMember |
|
|
|
|
|
|
|
|
|
|
| Amylin [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Proceeds from prepayment of revenue-sharing obligation |
|
|
|
|
|
|
|
|
|
|
|
|
1,210.0us-gaap_ProceedsFromSaleOfIntangibleAssets / us-gaap_ProductOrServiceAxis = lly_AmylinMember |
|
|
|
|
|
|
|
|
|
| Exenatide [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sales Revenue, Goods, Net |
|
|
|
|
|
|
|
|
|
|
133.1us-gaap_SalesRevenueGoodsNet / us-gaap_ProductOrServiceAxis = lly_ExenatideMember |
207.8us-gaap_SalesRevenueGoodsNet / us-gaap_ProductOrServiceAxis = lly_ExenatideMember |
|
|
|
|
|
|
|
|
|
|
| Collaboration and other revenue |
|
|
|
|
|
|
|
|
|
|
0us-gaap_OtherSalesRevenueNet / us-gaap_ProductOrServiceAxis = lly_ExenatideMember |
70.1us-gaap_OtherSalesRevenueNet / us-gaap_ProductOrServiceAxis = lly_ExenatideMember |
|
|
|
|
|
|
|
|
|
|
| Total Revenue |
|
|
|
|
|
|
|
|
|
|
133.1us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_ExenatideMember |
277.9us-gaap_Revenues / us-gaap_ProductOrServiceAxis = lly_ExenatideMember |
|
|
|
|
|
|
|
|
|
|
| Other Nonoperating Income (Expense) |
|
|
|
|
|
|
|
|
|
|
495.4us-gaap_OtherNonoperatingIncomeExpense / us-gaap_ProductOrServiceAxis = lly_ExenatideMember |
787.8us-gaap_OtherNonoperatingIncomeExpense / us-gaap_ProductOrServiceAxis = lly_ExenatideMember |
|
|
|
|
|
|
|
|
|
|
| Boerhringer Ingelheim (BI) [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaboration and other revenue |
|
|
|
|
|
|
|
|
|
328.8us-gaap_OtherSalesRevenueNet / us-gaap_ProductOrServiceAxis = lly_BoerhringerIngelheimBiMember |
249.2us-gaap_OtherSalesRevenueNet / us-gaap_ProductOrServiceAxis = lly_BoerhringerIngelheimBiMember |
88.6us-gaap_OtherSalesRevenueNet / us-gaap_ProductOrServiceAxis = lly_BoerhringerIngelheimBiMember |
|
|
|
|
|
|
|
|
|
|
| BI compounds [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Other-net, (income) expense |
|
92.0us-gaap_NonoperatingIncomeExpense / us-gaap_ProductOrServiceAxis = lly_BiCompoundsMember |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| LLY compounds [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Acquired in-process research and development |
|
55.2lly_AcquiredInProcessResearchAndDevelopment / us-gaap_ProductOrServiceAxis = lly_LlyCompoundsMember |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tanezumab [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Acquired in-process research and development |
|
|
|
|
|
|
|
|
|
|
|
|
|
200.0lly_AcquiredInProcessResearchAndDevelopment / us-gaap_ProductOrServiceAxis = lly_TanezumabMember |
|
|
|
|
|
|
|
|
| United States [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total Revenue |
|
|
|
|
|
|
|
|
|
9,134.1us-gaap_Revenues / us-gaap_StatementGeographicalAxis = country_US |
12,889.7us-gaap_Revenues / us-gaap_StatementGeographicalAxis = country_US |
12,313.1us-gaap_Revenues / us-gaap_StatementGeographicalAxis = country_US |
|
|
|
|
|
|
|
|
|
|
| Secured Note [Member] | Amylin [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Interest Rate, Stated Percentage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9.50%us-gaap_DebtInstrumentInterestRateStatedPercentage / us-gaap_ProductOrServiceAxis = lly_AmylinMember / us-gaap_TypeOfArrangementAxis = lly_SecuredNoteMember |
|
|
|
|
|
|
|
| Revenue Share [Member] | Amylin [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Arrangement, Rights and Obligations, Terms |
|
|
|
|
|
|
|
|
|
|
|
|
1,260.0lly_CollaborativeArrangementRightsAndObligationsTerms / us-gaap_ProductOrServiceAxis = lly_AmylinMember / us-gaap_TypeOfArrangementAxis = lly_RevenueShareMember |
|
1,200.0lly_CollaborativeArrangementRightsAndObligationsTerms / us-gaap_ProductOrServiceAxis = lly_AmylinMember / us-gaap_TypeOfArrangementAxis = lly_RevenueShareMember |
|
|
|
|
|
|
|
| Revenue Share [Member] | United States [Member] | Amylin [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Arrangement, Rights and Obligations Percent |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
65.00%lly_CollaborativeArrangementRightsAndObligationsPercent / us-gaap_ProductOrServiceAxis = lly_AmylinMember / us-gaap_StatementGeographicalAxis = country_US / us-gaap_TypeOfArrangementAxis = lly_RevenueShareMember |
|
|
|
|
|
|
|
| Revenue Share [Member] | Outside the United States [Member] | Amylin [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Arrangement, Rights and Obligations Percent |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
35.00%lly_CollaborativeArrangementRightsAndObligationsPercent / us-gaap_ProductOrServiceAxis = lly_AmylinMember / us-gaap_StatementGeographicalAxis = lly_OutsideUnitedStatesMember / us-gaap_TypeOfArrangementAxis = lly_RevenueShareMember |
|
|
|
|
|
|
|
| Milestone Payments [Member] | Solanezumab [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Arrangement, Rights and Obligations, Terms |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(70.0)lly_CollaborativeArrangementRightsAndObligationsTerms / us-gaap_ProductOrServiceAxis = lly_SolanezumabMember / us-gaap_TypeOfArrangementAxis = lly_MilestonePaymentsMember |
|
|
|
|
|
|
| Milestone Payments, Sales-based [Member] | Baricitinib [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Arrangement, Rights and Obligations, Terms |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(150.0)lly_CollaborativeArrangementRightsAndObligationsTerms / us-gaap_ProductOrServiceAxis = lly_BaricitinibMember / us-gaap_TypeOfArrangementAxis = lly_MilestonePaymentsSalesBasedMember |
|
|
|
|
|
| Milestone Payments, Sales-based [Member] | Tanezumab [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Arrangement, Rights and Obligations, Terms |
|
|
|
|
|
|
|
|
|
|
|
|
|
(1,230.0)lly_CollaborativeArrangementRightsAndObligationsTerms / us-gaap_ProductOrServiceAxis = lly_TanezumabMember / us-gaap_TypeOfArrangementAxis = lly_MilestonePaymentsSalesBasedMember |
|
|
|
|
|
|
|
|
| Milestone Payments, Development and Regulatory [Member] | Trajenta (BI) [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Arrangement, Rights and Obligations, Terms |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(478.7)lly_CollaborativeArrangementRightsAndObligationsTerms / us-gaap_ProductOrServiceAxis = lly_TrajentaBIMember / us-gaap_TypeOfArrangementAxis = lly_MilestonePaymentsDevelopmentAndRegulatoryMember |
|
|
|
|
| Milestone Payments, Development and Regulatory [Member] | Amylin [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Arrangement, Rights and Obligations, Terms |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
150.0lly_CollaborativeArrangementRightsAndObligationsTerms / us-gaap_ProductOrServiceAxis = lly_AmylinMember / us-gaap_TypeOfArrangementAxis = lly_MilestonePaymentsDevelopmentAndRegulatoryMember |
|
|
|
|
|
|
|
| Milestone Payments, Development and Regulatory [Member] | Jardiance [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Arrangement, Rights and Obligations, Terms |
|
|
|
|
|
|
|
|
|
(300.5)lly_CollaborativeArrangementRightsAndObligationsTerms / us-gaap_ProductOrServiceAxis = lly_JardianceMember / us-gaap_TypeOfArrangementAxis = lly_MilestonePaymentsDevelopmentAndRegulatoryMember |
(97.2)lly_CollaborativeArrangementRightsAndObligationsTerms / us-gaap_ProductOrServiceAxis = lly_JardianceMember / us-gaap_TypeOfArrangementAxis = lly_MilestonePaymentsDevelopmentAndRegulatoryMember |
|
|
|
|
|
|
|
|
|
|
|
| Milestone Payments, Development and Regulatory [Member] | LLY compounds [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Arrangement, Rights and Obligations, Terms |
|
|
|
|
|
|
|
|
|
(62.5)lly_CollaborativeArrangementRightsAndObligationsTerms / us-gaap_ProductOrServiceAxis = lly_LlyCompoundsMember / us-gaap_TypeOfArrangementAxis = lly_MilestonePaymentsDevelopmentAndRegulatoryMember |
50.0lly_CollaborativeArrangementRightsAndObligationsTerms / us-gaap_ProductOrServiceAxis = lly_LlyCompoundsMember / us-gaap_TypeOfArrangementAxis = lly_MilestonePaymentsDevelopmentAndRegulatoryMember |
|
|
|
|
|
|
|
(187.5)lly_CollaborativeArrangementRightsAndObligationsTerms / us-gaap_ProductOrServiceAxis = lly_LlyCompoundsMember / us-gaap_TypeOfArrangementAxis = lly_MilestonePaymentsDevelopmentAndRegulatoryMember |
|
|
|
| Milestone Payments, Development and Regulatory [Member] | Baricitinib [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Arrangement, Rights and Obligations, Terms |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(415.0)lly_CollaborativeArrangementRightsAndObligationsTerms / us-gaap_ProductOrServiceAxis = lly_BaricitinibMember / us-gaap_TypeOfArrangementAxis = lly_MilestonePaymentsDevelopmentAndRegulatoryMember |
|
|
(50.0)lly_CollaborativeArrangementRightsAndObligationsTerms / us-gaap_ProductOrServiceAxis = lly_BaricitinibMember / us-gaap_TypeOfArrangementAxis = lly_MilestonePaymentsDevelopmentAndRegulatoryMember |
|
|
| Milestone Payments, Development and Regulatory [Member] | Tanezumab [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Arrangement, Rights and Obligations, Terms |
|
|
|
|
|
|
|
|
|
|
|
|
|
(350.0)lly_CollaborativeArrangementRightsAndObligationsTerms / us-gaap_ProductOrServiceAxis = lly_TanezumabMember / us-gaap_TypeOfArrangementAxis = lly_MilestonePaymentsDevelopmentAndRegulatoryMember |
|
|
|
|
|
|
|
|
| Profit And Development And Marketing Share [Member] | Effient [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Arrangement, Rights and Obligations Percent |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
50.00%lly_CollaborativeArrangementRightsAndObligationsPercent / us-gaap_ProductOrServiceAxis = lly_EffientMember / us-gaap_TypeOfArrangementAxis = lly_ProfitAndDevelopmentAndMarketingShareMember |
|
| Upfront Payment [Member] | Amylin [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Arrangement, Rights and Obligations, Terms |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
250.0lly_CollaborativeArrangementRightsAndObligationsTerms / us-gaap_ProductOrServiceAxis = lly_AmylinMember / us-gaap_TypeOfArrangementAxis = lly_UpfrontPaymentMember |
|
|
|
|
|
|
|
| Sales Reported [Member] | Amylin [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Arrangement, Rights and Obligations Percent |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15.00%lly_CollaborativeArrangementRightsAndObligationsPercent / us-gaap_ProductOrServiceAxis = lly_AmylinMember / us-gaap_TypeOfArrangementAxis = lly_SalesReportedMember |
|
|
|
|
|
|
|
| Sales Reported [Member] | Outside the United States [Member] | Exenatide [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Arrangement, Rights and Obligations Percent |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
100.00%lly_CollaborativeArrangementRightsAndObligationsPercent / us-gaap_ProductOrServiceAxis = lly_ExenatideMember / us-gaap_StatementGeographicalAxis = lly_OutsideUnitedStatesMember / us-gaap_TypeOfArrangementAxis = lly_SalesReportedMember |
| Research And Development Exp [Member] | Baricitinib [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Arrangement, Rights and Obligations Percent |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
30.00%lly_CollaborativeArrangementRightsAndObligationsPercent / us-gaap_ProductOrServiceAxis = lly_BaricitinibMember / us-gaap_TypeOfArrangementAxis = lly_ResearchAndDevelopmentExpMember |
|
|
|
|
|
| Royalty Payments Received [Member] | Solanezumab [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Arrangement, Rights and Obligations, Term of Arrangement |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10 years |
|
|
|
|
|
|
| Royalty Payments Received [Member] | Baricitinib [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Arrangement, Rights and Obligations Percent |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
20.00%lly_CollaborativeArrangementRightsAndObligationsPercent / us-gaap_ProductOrServiceAxis = lly_BaricitinibMember / us-gaap_TypeOfArrangementAxis = us-gaap_RoyaltyAgreementTermsMember |
|
|
|
|
|
| Collaborative Arrangement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Marketing, selling, and administrative |
|
|
|
|
|
|
|
|
|
$ 211.2us-gaap_SellingGeneralAndAdministrativeExpense / us-gaap_TypeOfArrangementAxis = us-gaap_CollaborativeArrangementMember |
$ 203.7us-gaap_SellingGeneralAndAdministrativeExpense / us-gaap_TypeOfArrangementAxis = us-gaap_CollaborativeArrangementMember |
$ 188.5us-gaap_SellingGeneralAndAdministrativeExpense / us-gaap_TypeOfArrangementAxis = us-gaap_CollaborativeArrangementMember |
|
|
|
|
|
|
|
|
|
|